Galileo Biotech

We are deeply honored to have been selected as Biopharmaceutical Company of the Year 2024 for California by Global Health & Pharma (GHP). This recognition in GHP’s 2024 Biotechnology Awards is a testament to the dedication and efforts of our exceptional team at Antharis. It also motivates us to continue our mission of developing cutting-edge biotherapies for patients in need, worldwide.

Listed by The Silicon Review under ‘5 Best Biotech Companies to Watch 2024’, Discover how Antharis Therapeutics, Inc. innovates with tech to bridge therapy gap and counter pharma trends by empowering biotech firm. https://lnkd.in/gMhaBpzc #magazine #thesiliconreview #biopharma #immunology #cellularbiology #MolecularBiology #intellectualproperty #biotech

We are honored and sincerely grateful for the recognition of our CEO & Chairman, Dr. Raphael R Pinaud, PhD, MBA, as the "Most Inspiring Business Leader - 2024". This accolade not only attests to Dr. Ribeiro-Pinaud’s vision, unparalleled energy, and commitment to our company and to excellence, but also mirrors the collective hard work and dedication of our entire team. This recognition further propels us in the pursuit of excellence, and inspires the team to consistently challenge limits and strive to transform the lives of patients and families affected by devastating diseases. We thank CXO Outlook® for acknowledging and celebrating the journey of our CEO & Chairman. Congratulations Dr. Ribeiro-Pinaud! https://lnkd.in/g8fC-5gJ

We are delighted to witness the recognition of Antharis’ outstanding work acknowledged among the “Top 5 Biotech Companies to Watch For in 2024” by industry executives. We would especially like to thank our CEO & Chairman, Dr. Raphael R Pinaud, PhD, MBA, for his unwavering commitment, leadership, and strategic guidance, to our Director of Operations Cass Morrison, to our scientific leaders, Dr. Eric Sjoberg and Dr. Jinming Xia, as well as the entire Antharis Therapeutics, Inc. and Galileo Biotech teams, for their dedication and commitment to scientific excellence. Irrespective of Antharis’ recent recognitions, our team remains fully devoted to advancing the next generation of biotherapies directed at devastating diseases, to benefit patients in need, globally. #biopharma #monoclonalantibodies #adc #cancer #cancerresearch

Exciting news! We are honored to have been voted as one of the top 10 biotech startup companies of 2023 by Pharma Tech Outlook. We are proud of our founder and CEO, Dr. Raphael R Pinaud, PhD, MBA, and the amazing Antharis Therapeutics, Inc. team at the forefront of our efforts to develop the next generation of biotherapies against severe diseases, to benefit patients in need, globally. We look forward to the journey that lies ahead and congratulate all other companies that were voted to be part of this select group! For the full article, see: https://lnkd.in/grf6GWeR